Clinical trials: Sarcoma Metastatic, open to volunteers
Advanced Alveolar Soft Part Sarcoma, Advanced Soft Tissue Sarcoma
Testing Atezolizumab With Selinexor in People ≥ 12 Years Old With Alveolar Soft Part Sarcoma, AXIOM Trial
This phase II trial tests whether atezolizumab in combination with selinexor works to shrink tumors in patients with alveolar soft part sarcoma and whether the study drugs are better than the usual approach in treating this type…
- Conditions
- Advanced Alveolar Soft Part Sarcoma, Advanced Soft Tissue Sarcoma, Metastatic Alveolar Soft Part Sarcoma, Refractory Alveolar Soft Part Sarcoma
- Trial name
- NCT05333458
- Testing
- Atezolizumab, Biopsy Procedure, Biospecimen Collection
- Where
- 13 sites in United States
- Volunteers
- 27 people
- Sponsor
- National Cancer Institute (NCI)
Bone Sarcomas
A Phase 2 Trial of Zanzalintinib in Advanced/Metastatic Bone Sarcomas (ZAMBONE)
To study the treatment efficacy of zanzalintinib monotherapy in patients with advanced and/or metastatic bone sarcomas.
- Trial name
- NCT07193550
- Testing
- Zanzalintinib
- Where
- United States
- Volunteers
- 70 people
- Sponsor
- M.D. Anderson Cancer Center
Advanced or Metastatic Solid Tumor, Pancreatic Ductal Adenocarcinoma
AB122 Platform Study
This is a phase 1, non-randomized open-label, multicenter platform study designed to evaluate the tolerability and safety of AB122 in patients with malignancies specified in each cohort.
- Conditions
- Advanced or Metastatic Solid Tumor, Pancreatic Ductal Adenocarcinoma, Colorectal Cancer, Non-small Cell Lung Cancer
- Trial name
- NCT04999761
- Testing
- AB122, TAS-116, TAS-120
- Where
- 9 sites in Japan
- Volunteers
- 917 people
- Sponsor
- Taiho Pharmaceutical Co., Ltd.
Soft Tissue Sarcoma (STS)
A Phase Ib/II Study to Evaluate Safety and Efficacy of Bexmarilimab in Combination With Doxorubicin in Metastatic Soft-tissue Sarcoma.
This trial will Study a type of sarcoma defined metastatic soft-tissue sarcoma (STS). Participants will be treated with bexmarilimab, a CLEVER-1 antibody plus doxorubicin, a chemotherapy.
- Trial name
- BEXAR (NCT07460986)
- Testing
- bexmarilimab, Doxorubicin
- Where
- 11 sites in Spain
- Volunteers
- 278 people
- Sponsor
- MedSIR
Breast Cancer, Lung Cancer
Investigating the Effects of Atezolizumab in People Whose Tumour DNA or RNA Indicates Possible Sensitivity
This study will investigate the effects of atezolizumab on select cancer types in people whose analysis of tumour DNA and RNA indicates they may be sensitive to atezolizumab.
- Conditions
- Breast Cancer, Lung Cancer, Gastrointestinal Cancer, Genitourinary Cancer
- Trial name
- CAPTIV-8 (NCT04273061)
- Testing
- Atezolizumab
- Where
- 2 sites in Canada
- Volunteers
- 50 people
- Sponsor
- British Columbia Cancer Agency
Metastatic Sarcoma, Recurrent Sarcoma
Implantable Microdevice for the Delivery of Drugs and Their Effect on Tumors in Patients With Metastatic or Recurrent Sarcoma
This early phase I trial studies the side effects of implanting and removing a microdevice in patients with sarcomas that have spread to other places in the body (metastatic) or have come back (recurrent).
- Conditions
- Metastatic Sarcoma, Recurrent Sarcoma, Resectable Sarcoma
- Trial name
- NCT04199026
- Testing
- Doxorubicin, Doxorubicin Hydrochloride, Drug Delivery Microdevice
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- M.D. Anderson Cancer Center
Metastatic Sarcoma, Radiation Therapy Patient
Targeted Oligometastatic Radiation in Pediatric and Young Adult Patients With Soft Tissue and Bone Sarcoma
This study is designed for children, adolescents and young adults undergoing radiation therapy for metastatic sarcoma. The aim of the study is to investigate if the investigators can improve the overall survival of these patients…
- Conditions
- Metastatic Sarcoma, Radiation Therapy Patient, Ewing Sarcoma, Rhabdomyosarcoma
- Trial name
- TARGET-RT (NCT06796543)
- Testing
- Consolidative radiation therapy (cRT)
- Where
- 3 sites in United States
- Volunteers
- 70 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Metastatic Myxoid Liposarcoma, Metastatic Synovial Sarcoma
Testing the Anti-Cancer Drug, Brenetafusp (IMCF106C), in Rare Cancers
This phase II trial studies how well brenetafusp (IMC-F106C) works in treating patients with preferentially expressed antigen of melanoma (PRAME) positive synovial sarcoma and myxoid/round cell liposarcoma that has spread from…
- Conditions
- Metastatic Myxoid Liposarcoma, Metastatic Synovial Sarcoma, Unresectable Myxoid Liposarcoma, Unresectable Synovial Sarcoma
- Trial name
- NCT07686367
- Testing
- Anti-PRAME T-cell Receptor/Anti-CD3 scFv Fusion Protein IMC-F106C, Biopsy Procedure, Biospecimen Collection
- Volunteers
- 42 people
- Sponsor
- National Cancer Institute (NCI)
Cancer, Advanced Cancer
A Study to Evaluate Safety, Tolerability and Preliminary Activity of AGX101 in Participants With Advanced Solid Tumors
AGX101 is an antibody-drug conjugate (ADC) therapy for tumor-forming cancers. The purpose of this study is to learn about AGX101 effects and safety at various dose levels in an all-comers advanced solid cancer patient population.
- Conditions
- Cancer, Advanced Cancer, Locally Advanced Carcinoma, Metastatic Solid Tumor
- Trial name
- NCT06440005
- Testing
- AGX101
- Where
- 7 sites in United States
- Volunteers
- 80 people
- Sponsor
- Angiex, Inc.
Metastatic Leiomyosarcoma, Unresectable Leiomyosarcoma
XL092 (Zanzalintinib) for the Treatment of Patients With Metastatic or Unresectable Leiomyosarcoma, Bone Sarcoma or Translocation-associated Soft Tissue Sarcoma
This phase II trial tests how well zanzalintinib (XL092) works in treating patients with leiomyosarcoma that has spread from where it first started to other places in the body (metastatic) or that cannot be removed by surgery…
- Conditions
- Metastatic Leiomyosarcoma, Unresectable Leiomyosarcoma, Bone Sarcoma, Translocation-associated Soft Tissue Sarcoma
- Trial name
- NCT06571734
- Testing
- Biospecimen Collection, Computed Tomography, Echocardiography
- Where
- United States
- Volunteers
- 73 people
- Sponsor
- Northwestern University
Osteosarcoma, Pediatric Osteosarcoma
Fight Osteosarcoma Through European Research Evolving Study Platform From Diagnosis to Relapse
This clinical study is the initiative of the FOSTER (Fight OsteoSarcoma Through European Research) consortium and Gustave Roussy, which is the sponsor.
- Conditions
- Osteosarcoma, Pediatric Osteosarcoma, Osteosarcoma in Children, Osteosarcoma in Adolescents and Young Adults
- Trial name
- FOSTER (NCT07871864)
- Testing
- Experimental group : Cabometyx ® 40mg/m2/day (Max: 60mg/day) , Treatment schedule : Daily**, day 1-28 during 4 weeks (ie. 1 cycle) during 12 cycles
- Where
- 77 sites in Denmark, Finland and 6 more
- Volunteers
- 530 people
- Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
Locally Advanced Soft Tissue Sarcoma
A Prospective, Single-arm, Multicenter Exploratory Clinical Study of Anlotinib Combined With Bempegaldesleukin and Conventional Chemoradiotherapy for the Treatment of Unresectable Locally Advanced or Metastatic Soft Tissue Sarcoma.
This study employs a multicenter, single-arm trial design. Participants will receive a treatment regimen consisting of "anlotinib plus bempegaldesleukin concurrent with radiotherapy," followed by a maintenance therapy phase of…
- Trial name
- NCT07156643
- Testing
- Anlotinib and bempegaldesleukin
- Where
- China
- Volunteers
- 46 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Osteosarcoma, Metastatic Bone Disease
Musculoskeletal Cancers Remote Monitoring and Care
This study aims to evaluate how walking stability and the ability to perform daily activities change during cancer treatment, and whether a smartwatch can detect these changes.
- Trial name
- NCT07129226
- Testing
- Smart Watch
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Case Comprehensive Cancer Center
Sarcoma, Sarcoma, Kaposi
Sequential Infusion of CD146-Targeted and HER2-Targeted CAR T Cells in Patients With Advanced Sarcomas
This is an open-label, non-randomized, multicenter Phase 1/2 trial evaluating a dual CAR-T cell therapy targeting CD146 and HER2 in patients with advanced sarcoma.
- Conditions
- Sarcoma, Sarcoma, Kaposi, Sarcoma, Ewing, Sarcoma,Soft Tissue
- Trial name
- BAH2573-103 (NCT07066982)
- Testing
- CD146/HER2 CAR-T cells
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Essen Biotech
Endometrial Neoplasms, Ovarian Neoplasms
A Study of Catequentinib Hydrochloride (AL3818) in Endometrial, LGSOC, STS or GBM Cancers
This phase 1b/2a study evaluates the investigational oral drug catequentinib hydrochloride (AL3818), given alone or with AL58805, temozolomide, or lomustine (CCNU), in adults with advanced or metastatic solid tumors.
- Conditions
- Endometrial Neoplasms, Ovarian Neoplasms, Soft Tissue Sarcoma (STS), Glioblastoma
- Trial name
- NCT07811297
- Testing
- AL58805, AL3818, Temozolomide (TMZ)
- Where
- United States
- Volunteers
- 138 people
- Sponsor
- Advenchen Pharmaceuticals, LLC.
Head and Neck Squamous Cell Carcinoma (HNSCC) - Recurrent/Metastatic (R/M), Nasopharyngeal Carcinoma
Phase I Study of Becotatug Vedotin for Safety and Efficacy in EGFR-Positive Pediatric Relapsed/Refractory or Metastatic Solid Tumors
There is a significant unmet medical need for effective therapies for pediatric relapsed/refractory solid tumors. EGFR is highly and stably expressed in multiple pediatric solid tumor subtypes, and adult Phase I data of Becotatug…
- Conditions
- Head and Neck Squamous Cell Carcinoma (HNSCC) - Recurrent/Metastatic (R/M), Nasopharyngeal Carcinoma, Lymphoepithelial Carcinoma, Rhabdomyosarcoma
- Trial name
- MRG003 (NCT07584499)
- Testing
- Becotatug Vedotin
- Where
- China
- Volunteers
- 51 people
- Sponsor
- Sun Yat-sen University
Cancer, Sarcoma
EBNK-001 Allogeneic NK Cells With Low-Dose IL-15 ± Pembrolizumab in Advanced Solid Tumors
This Phase 1/2 study evaluates the safety, tolerability, and preliminary anti-tumor activity of EBNK-001 (allogeneic NK cells) given after lymphodepleting cyclophosphamide/fludarabine (CY/FLU) and supported with low-dose IL-15…
- Conditions
- Cancer, Sarcoma, Leukaemia, Breast Cancer (Locally Advanced or Metastatic)
- Trial name
- EBNK-ST-001 (NCT07410676)
- Testing
- EBNK-001 + IL-15 + Pembrolizumab
- Where
- China
- Volunteers
- 83 people
- Sponsor
- Essen Biotech
Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage III Cutaneous Merkel Cell Carcinoma AJCC v8
Low Dose, Reduced Frequency Nivolumab for the Treatment of Unresectable or Metastatic Cancer, AFFORD IO Trial
This phase II trial studies how well low dose, reduced frequency nivolumab works in treating patients with cancer that cannot be removed by surgery (unresectable) or that has spread from where it first started (primary site) to…
- Conditions
- Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage III Cutaneous Merkel Cell Carcinoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Merkel Cell Carcinoma AJCC v8
- Trial name
- NCT07576725
- Testing
- Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging
- Where
- Uganda
- Volunteers
- 50 people
- Sponsor
- Fred Hutchinson Cancer Center
Alveolar Soft Part Sarcoma, Leiomyosarcoma
Phase III Trial of Anlotinib, Catequentinib in Advanced Alveolar Soft Part Sarcoma, Leiomyosarcoma, Synovial Sarcoma (APROMISS)
THIS STUDY IS CURRENTLY RECRUITING PATIENTS WITH ALVEOLAR SOFT PART SARCOMA ONLY AND IS NO LONGER RECRUITING PATIENTS WITH SYNOVIAL SARCOMA OR LEIOMYOSARCOMA.
- Conditions
- Alveolar Soft Part Sarcoma, Leiomyosarcoma, Synovial Sarcoma, Soft-Tissue Sarcoma
- Trial name
- APROMISS (NCT03016819)
- Testing
- AL3818, Dacarbazine, Midazolam 2 mg for CYP3A4 phenotyping
- Where
- 24 sites in United States, China and 3 more
- Volunteers
- 325 people
- Sponsor
- Advenchen Laboratories, LLC
Phase 2, Zanzalintinib
Phase 2 Trial of Zanzalintinib and Pembrolizumab in Select Subtypes of Advanced/Metastatic Soft-tissue Sarcoma
To learn if zanzalintinib and pembrolizumab can help to control select subtypes of advanced/metastatic soft-tissue sarcoma (UPS, MFS, HGPS, and HGUS
- Conditions
- Phase 2, Zanzalintinib, Pembrolizumab, Advanced/Metastatic
- Trial name
- NCT07283731
- Testing
- Zanzalintinib, Pembrolizumab
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- M.D. Anderson Cancer Center